Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients.

Clinical trial NCT05740150 · UNKNOWN

Trial details

NCT number: NCT05740150
Sponsor: Princess Maxima Center for Pediatric Oncology
Status: UNKNOWN
Phase: Not Applicable
Study type: INTERVENTIONAL

Central Line-associated Bloodstream Infection (CLABSI)

Start date: 2020-10-27
Primary completion: 2023-12-01
Enrollment: 462

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.